Physician profile
Heather A Hancock
NPI 1821120072
$38,596.79
in general payments reported to CMS, 2019-2025
16 companies · $22K in 2025
The $22K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $98.47 · 2021: $98.03 · 2022: $516 · 2023: $891 · 2024: $15K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Food and Beverage: $3,557 · Travel and Lodging: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,050.00 |
| Food and Beverage | $3,556.98 |
| Travel and Lodging | $133.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $35,938.39 | 2021-2025 | Acthar |
| Abbvie INC. | $440.89 | 2022-2025 | |
| Alcon Vision LLC | $432.45 | 2023-2024 | Ngenuity, Clareon, Lensx |
| Apellis Pharmaceuticals, INC. | $343.98 | 2022-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $337.61 | 2019-2025 | Eylea Hd |
| Ani Pharmaceuticals, INC. | $206.73 | 2023-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Inspire Medical Systems, INC. | $192.47 | 2025 | Inspire |
| Allergan, INC. | $184.88 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $98.22 | 2024 | Eylea Hd |
| Alimera Sciences, INC. | $87.53 | 2023-2024 | Iluvien, Yutiq |
| Glaukos Corporation | $81.19 | 2024 | Idose |
| Astellas Pharma US INC | $80.82 | 2023-2025 | Izervay |
| Genentech USA, INC. | $67.24 | 2019-2025 | Vabysmo |
| Ocular Therapeutix, INC. | $37.68 | 2024-2025 | Dextenza |
| Boston Scientific Corporation | $33.76 | 2023-2024 | Artisan |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $32.95 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Hancock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.